Drug Trial Radar · NCT06481098
A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.
Last checked: Nov 19, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
May 28, 2024
Primary completion
May 2, 2025
Study completion May 2, 2025
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Study is a Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects.
Conditions
- Obesity
Interventions
HM15275Drug
HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
Placebo of HM15275Drug
A sterile, matching solution supplied in pre-filled syringes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and TolerabilityTime frame: Up to Day 29
- Part B: Safety and TolerabilityTime frame: Up to Day 57
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ProSciento, Inc.
Chula Vista, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.